City Therapeutics

News

RNAi biotech City hauls in $200m in upsized IPO

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

News

Bambusa, Aspen, and Tang added to IPO pipeline

2026's sizeable haul of IPOs shows no signs of letting up, with three more biotechs – Bambusa, Aspen, and blank cheque firm Tang – joining the queue.

News

SonoThera's $125m Series B heads recent biofinancings

Our latest roundup of financings in the biotech sector includes impressive rounds for SonoThera, Ethyreal, CeQur, and City Therapeutics.

News

City Therapeutics' $135m debut, and other bio financing news

Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by biotech doyen John Maraganore, and additional cash for Purespring, J

RNAi biotech City hauls in $200m in upsized IPO

Bambusa, Aspen, and Tang added to IPO pipeline

SonoThera's $125m Series B heads recent biofinancings

City Therapeutics' $135m debut, and other bio financing news

On the benefits of earlier oncological intervention, with Jo...

Discover a new era of healthcare panel engagement: Grounded ...

City Therapeutics

Editor's Picks